Cns Pharmaceuticals Inc (CNSP NASDAQ) stock market data APIs
$9.0792
0.02(0.2%)
as of September 16, 2025
Try our APIs with
free plan!
Cns Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Prev. Close
9.0792
Open
9.1039
High
9.142
Low
8.296
52 wk Range
4.93-114
Market Cap
5 252 K
P/E Ratio
0.0043
Shares Outstanding
575 K
EPS
-6.42
Beta
0.643
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cns Pharmaceuticals Inc data using free add-ons & libraries
Get Cns Pharmaceuticals Inc Fundamental Data
Cns Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -15 572 062
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -9.6
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cns Pharmaceuticals Inc News
New
CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap
As previously reported, Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy from Hold with a $20 price target The company has pivoted to its oncology asset TPI-287, a blood brain barrier crossing taxane ...
Envista Holdings Breaks Below 200-Day Moving Average - Notable for NVST
In trading on Thursday, shares of Envista Holdings Corp (Symbol: NVST) crossed below their 200 day moving average of $19.02, changing hands as low as $18.88 per share. Envista Holdings Corp shares ar...
CNS Pharmaceuticals Announces Reverse Stock Split
HOUSTON, TX / ACCESS Newswire / July 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pr...
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
